RNTX

0.33698.38%
RJ

Reinhard J. Ambros

Independent Lead Director

Dr. Reinhard J. Ambros, Ph.D., served as Chairman of the Board at TOLREMO therapeutics AG. He serves as the Chairman of the Board at ImmunOs Therapeutics AG and serves as its Chief Executive Officer since June 2024. Dr. Ambros has been a Director of Synthetic Genomics, Inc. since June 2018. He is an Advisor at Charlbury Animal Health Capital GmbH. He also served as Director of Affluent Medical SA. Dr. Ambros served as the President of the Novartis Venture Funds. Dr. Ambros served as the Managing Director and Executive Director at Novartis Venture Funds and served as its Global Head from August 2005 to September 2017. Dr. Ambros was previously Founder and Global Head of the Novartis Venture Fund, where he built one of the largest and most active corporate Biotechnology Funds. Dr. Ambros retired from Novartis where he built, over the past many years. He previously served as Head of Group Strategic Planning for Novartis Corporation (Novartis Corporate Finance) from 2001 to 2005. He served as the Global Head of Business Development and Licensing for Cardiovascular and Metabolic Diseases at Novartis Pharma AG. Dr. Ambros was responsible for post-merger integrations at Novartis Corporate M&A. Dr. Ambros had global leadership positions for key drug development projects at Novartis AG and Roche. He works with Catalyst Biosciences Inc., ESBATech and NovImmune. He served as Global Head of Business Development at Novartis AG. He served as the Chairman of Genedata AG. Dr. Ambros serves as a Director of Genedata AG, Novartis Option Fund and served as Director at Forma Therapeutics Holdings LLC. He has been a Director of Rein Therapeutics Inc. (formerly known as Aileron Therapeutics, Inc.) since June 2013 and has been its Lead Independent Director since March 2018. He served as a Director at Symetis SA since February 29, 2008. He served as a Director of MicroCHIPS Biotech, Inc. since April 2007 and Protemix Corporation Limited. He served as Director of FORMA Therapeutics, Inc. until June 23, 2017. He served as Director of Aerpio Pharmaceuticals, Inc. (formerly Aerpio Therapeutics, Inc.). He served as a Director of Tokai Pharmaceuticals, Inc. since May 2009. He served as a Director of Cylene Pharmaceuticals, Inc. since January 23, 2007. Throughout his career, Dr. Ambros has gained broad experience in international leadership positions in venture capital, corporate strategy, BD&L and pharmaceutical product development. He serves on the board of public and private bio-technology companies in Europe and the USA. He also serves as Advisor to German and Swiss government biotechnology funds. Dr. Ambros is trained as a Pharmacist. Dr. Ambros received an M.S. from the University of Regensburg, Germany and a Ph.D. in Medicinal Chemistry and Pharmacology from the University of Regensburg, Germany.

Positions